Dumping drug discovery makes Tysabri-rich Elan tastier takeover target
This article was originally published in Scrip
Elan could look like an attractive takeover target for a big pharma or biotech company looking for an uncomplicated profit boost, now that it has announced plans to split out its profitable Tysabri and later-stage assets from its early-stage drug discovery business and cut its workforce down from 380 to around 170-190 across the two firms. The front-runner for potential bids would indeed probably be its Tysabri partner Biogen Idec.
You may also be interested in...
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.